Background
==========

Breast cancer (BC) remains the highest occurring cancer in women, in addition to being the third most frequent malignancy globally. In 2012, around 1.7 million persons worldwide had BC and nearly 500,000 died from the disease \[[@b1-medscimonit-24-9442]--[@b4-medscimonit-24-9442]\]. One among eight or 10 women will develop BC in their lifetime. BC mortality has decreased in North America as well as the European Union, but is still increasing in South America, Africa, and Asia. BC is the most common cause of cancer mortality in developing countries, compared with lung cancer in developed countries \[[@b5-medscimonit-24-9442]--[@b7-medscimonit-24-9442]\]. Genetic aspects and environmental exposure play a significant part in the etiology of BC \[[@b8-medscimonit-24-9442],[@b9-medscimonit-24-9442]\]. The Human Genome Project has led to increasing attention being paid to cancer genetic susceptibility. A genetic factor which dysfunction amid normal tissues and tumors in the genome are the major potential sources of prognostic and diagnostic biomarkers \[[@b10-medscimonit-24-9442]\]. Also, genes whose expression is interlinked with survival of BC might be prognostic biomarkers, as well as therapeutic targets \[[@b11-medscimonit-24-9442]--[@b14-medscimonit-24-9442]\]. As in other malignant neoplastic diseases, BC is considered to have dysfunction of numerous gene signaling pathways as well as networks that have an impact on tissue homeostasis.

There are 45 kinesin superfamily proteins (KIFs) with various functions in humans \[[@b15-medscimonit-24-9442]\]. KIFs are involved in the molecular movements of axonal transportation. KIFs are ubiquitous in eukaryotes, and some are involved in transportation of vesicles and organelles inside cells \[[@b16-medscimonit-24-9442],[@b17-medscimonit-24-9442]\]. KIF genes have been shown to play a crucial role in many tumors, and can be used to predict cancer diagnosis and prognosis \[[@b18-medscimonit-24-9442],[@b19-medscimonit-24-9442]\] . It has been shown that the KIF family of genes is linked with BC \[[@b20-medscimonit-24-9442],[@b21-medscimonit-24-9442]\], nevertheless, the joint analysis linked with multiple KIF family genes regarding BC have rarely been recorded. Complete examination of the diagnostic and prognostic values of KIF genes in BC requires additional investigation. The purpose of the present study was to explore the diagnostic and prognostic values of KIF gene expression in BC patients, on the basis of bioinformatics evaluation.

Material and Methods
====================

Bioinformatics analysis of KIF genes
------------------------------------

For analysis of the biological pathways and significance of the KIF family genes, a set of functional enrichment analysis for the KIF family was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID 6.8, *<https://david.ncifcrf.gov/home.jsp>*, accessed August 3, 2018). Enriched P values \<0.05 were statistically significant. Gene--gene interactions of KIF family genes were investigated via GeneMANIA (*<http://www.genemania.org/>*, accessed August 9, 2018) \[[@b22-medscimonit-24-9442]\]. Protein--protein interactions were examined by the Search Instrument for the Retrieval of Interacting Genes/Proteins (STRING, *<https://string-db.org/>*, accessed August 9, 2018) \[[@b23-medscimonit-24-9442]\]. We also applied the Cytoscape (version 3.6.1) Biological Networks Gene Ontology (BiNGO) instrument for performing Gene Ontology (GO) evaluation on the KIF gene family \[[@b24-medscimonit-24-9442]\].

Data source
-----------

The knowledge of the clinical of BC patients and RNA sequence based on the patients were gathered by the Cancer Genome Atlas (TCGA) database (*<https://cancergenome.nih.gov/>*, accessed June 7, 2018). Using the edgeR package in R, we normalized mRNA sequencing data and examined mRNA expression in normal tissues and BC. Genes with an accustomed P value \<0.01 and \|log~2~ fold-change (FC)\| \>2 were considered to be significantly different in BC and adjacent tissues. We regarded the genes as being differentially expressed mRNA (DEM). Clinical characteristics of patients with BC included gender, ethnicity (Asian, black, white or other), age at diagnosis (\<65 or ≥65 years), and tumor stage.

Survival analysis
-----------------

For each KIF DEM, patients were divided into low- and high-expression groups according to the median expression values of each KIF genes. By utilizing survival curves by Kaplan-Meier analysis with log-rank test, we assessed the prognostic significance of every clinical aspect as well as DEM from a criterion of P\<0.05. The Cox proportional hazards model was utilized for evaluating the comparative risk in such differentially expressed genes on overall survival (OS). The mRNAs significantly associated with OS in the Cox proportional hazards model were considered to be prognostic mRNAs.

Correlation analysis
--------------------

Pearson correlation coefficient was assessed for identifying correlations between the prognostic mRNAs.

Joint-effects analysis and nomograms
------------------------------------

To assess thoroughly the prognostic model, joint analysis and nomograms were performed on the KIF DEM prognostic signature. On the basis of previous survival analysis, we divided the combined genes into high-, intermediate- and low-risk groups, completed survival analysis on 3 groups of patients, and established a Cox regression model. In addition to the joint analysis, we examined the predictive prognostic value of the risk scoring using nomograms to assess the correlation among clinical status as well as risk score within BC OS. The possible implication of risk scoring on the basis of predicting clinical characteristics has similarly been discovered. C-index and calibration curve were considered with bootstrap self-sampling and internal verification.

Gene set enrichment analysis (GSEA)
-----------------------------------

The core concept in GSEA is to utilize a predefined group of genes (mainly by previous experimental outcomes or functional annotations) for ranking the genes in accordance with the extent of differential expression within the 2 types of samples, then verifying that the pre-established group of genes is supplemented at the bottom or top in the sorting table. To explore the differences in pathways as well as biological functions in the low- and high-expression sets of such prognostic KIF genes, GSEA (*<http://software.broadinstitute.org/gsea/index.jsp>*, accessed August 9, 2018) \[[@b25-medscimonit-24-9442],[@b26-medscimonit-24-9442]\] was used to explore potential KEGG pathway and GO analysis within the Molecular Signatures Database (MSigDB) of c2 (curated gene sets) and c5 (GO gene sets) \[[@b27-medscimonit-24-9442]\]. The criteria for significant enrichment gene sets in GSEA were: P\<0.05 and false discovery rate (FDR) \<0.25.

Statistical analysis
--------------------

Log-rank assessment was utilized for comparing clinical aspects as well as univariate survival analysis of KIF genes. Clinicopathological parameters statistically linked to OS (P\<0.05) were included in multivariate Cox proportional hazard regression models to adjust. Hazard ratios (HRs) and 95% confidence intervals (CIs) were used to assess the relative risk in many patients with BC. Multiple testing with the Benjamini--Hochberg procedure was used to control the FDR in GSEA. Statistical analysis was performed using SPSS 22.0 and R 3.5.1 software. P\<0.05 was considered to be statistically significant.

Results
=======

Bioinformatics analysis of the KIF family genes
-----------------------------------------------

Enrichment analysis of GO terms for the KIF family genes, performed with DAVID, showed that KIF genes had suggestive enrichment for microtubule-based movement, and biological functions mainly included mitotic metaphase plate congression, mitotic cytokinesis, mitotic spindle assembly, cell division, mitotic spindle midzone assembly, and positive regulation of cytokinesis ([Figure 1](#f1-medscimonit-24-9442){ref-type="fig"}). Gene--gene and protein--protein interaction networks confirmed that the KIF genes had solid protein homology as well as co-expression with one another at the protein as well as gene levels ([Figure 2A, 2B](#f2-medscimonit-24-9442){ref-type="fig"}). The focused KIF genetic acyclic graph constructed by BiNGO in Cytoscape similarly showed that the main biological roles were cell cycle progression, cellular processes, and microtubule-based processes ([Figure 2C](#f2-medscimonit-24-9442){ref-type="fig"}).

Patient characteristics influencing differential KIF expression in BC
---------------------------------------------------------------------

The \|log~2~FC\| of KIF family is shown in a histogram ([Figure 3A](#f3-medscimonit-24-9442){ref-type="fig"}). Thirteen KIF family genes met the standard of FDR \<0.05 together with \|log~2~FC\| ≥2 ([Table 1](#t1-medscimonit-24-9442){ref-type="table"}). A scatter plot produced using TCGA showed the difference in expression of the 13 KIF genes in invasive BC tissues compared with normal breast tissues ([Figure 3B](#f3-medscimonit-24-9442){ref-type="fig"}). Therefore, only the remaining 13 mRNAs were included in the step function screening to investigate the optimal combination, and all the mRNA expression data were log~2~ transformed for further analysis. The KIF genetic ROC analysis in the TCGA cohort specified that every KIF gene was highly accurate for discriminating normal breast and tumor tissues (area under the curve for the ROC curves in 11 KIF genes remained \>0.9; [Figure 4](#f4-medscimonit-24-9442){ref-type="fig"}, [Table 1](#t1-medscimonit-24-9442){ref-type="table"}).

Survival analysis and association analysis
------------------------------------------

In the TCGA invasive BC cohort, patients with advanced tumor stage and age ≥65 years had an increased risk of invasive BC mortality ([Table 2](#t2-medscimonit-24-9442){ref-type="table"}). Other patient characteristics, including gender and race, within the TCGA cohort did not show a significant association with OS of invasive BC.

Survival analysis of the 13 differentially expressed KIF genes is shown in [Table 3](#t3-medscimonit-24-9442){ref-type="table"}. Patients with low expression of *KIF15*, *KIF20A*, *KIF23*, *KIF2C* and *KIF4A* genes in the TCGA invasive BC cohort had an extended OS ([Table 3](#t3-medscimonit-24-9442){ref-type="table"}, [Figure 5A--5E](#f5-medscimonit-24-9442){ref-type="fig"}). However, only the *P* values of *KIF4A* reached significance (P=0.008). It was suggested that elevated expression of *KIF15* (adjusted *P*=0.045; adjusted HR=1.422; 95% CI=1.007--2.008), *KIF20A* (adjusted *P*=0.03; adjusted HR=1.467; 95% CI=1.038--2.072), *KIF23* (adjusted *P*=0.014; adjusted HR=1.54; 95% CI=1.09--2.175), *KIF2C* (adjusted *P*=0.001; adjusted HR=1.805; 95% CI=1.276--2.553) and *KIF4A* (adjusted *P*=0.001; adjusted HR=1.805; 95% CI=1.276--2.553) ([Table 3](#t3-medscimonit-24-9442){ref-type="table"}) was related to poor OS within invasive BC, after adjusting for tumor stage and age.

After performing survival analysis within the TCGA cohorts, co-expression analysis of *KIF15*, *KIF20A*, *KIF23*, *KIF2C* and *KIF4A* in BC malignant tissues was evaluated using Pearson's correlation coefficient. The genes were co-expressed strongly with each other in the TCGA cohort ([Figure 6](#f6-medscimonit-24-9442){ref-type="fig"}).

Effect of combinations of KIF gene expression on OS
---------------------------------------------------

Based on KIF gene survival analysis, *KIF15*, *KIF20A*, *KIF23*, *KIF2C* and *KIF4A* were screened as prognostic genes by multivariate survival analysis. A joint-effects model was utilized for determining the combined influence of the 5 KIF genes on OS of BC patients. The diverse groups for this analysis were generated in accordance with expression of *KIF15*, *KIF20A*, *KIF23*, *KIF2C* and *KIF4A* ([Tables 4](#t4-medscimonit-24-9442){ref-type="table"}[](#t5-medscimonit-24-9442){ref-type="table"}[](#t6-medscimonit-24-9442){ref-type="table"}--[7](#t7-medscimonit-24-9442){ref-type="table"}). The Kaplan-Meier estimator with a log-rank evaluation was administered to evaluate the prognostic significance of the gene expression combinations represented by each group. Two selected groups showed that the BC patients with high expression of *KIF20A* and *KIF4A* or high expression of *KIF2C* and *KIF4A* had poor OS ([Table 8](#t8-medscimonit-24-9442){ref-type="table"}). Within the evaluation of low *KIF15*, *KIF20A*, *KIF23*, *KIF2C* and low *KIF4A* expression, the combinations in groups 4, 7, 10, 13, 16, 19, 22, 25 and 28 were highly correlated with favorable OS (all *P*\<0.05; [Table 8](#t8-medscimonit-24-9442){ref-type="table"}). In the analysis of high expression of *KIF15*, *KIF20A*, *KIF23*, *KIF2C* and *KIF4A*, the combinations in groups 3, 6, 9, 12, 15, 18, 21, 24, 27 and 30 were highly correlated with poor OS (all *P*\<0.05; [Table 8](#t8-medscimonit-24-9442){ref-type="table"}).

GSEA
----

GSEA of the prognostic genes *KIF15*, *KIF20A*, *KIF23*, *KIF2C* and *KIF4A* was performed within the TCGA cohorts. The expression profiles of the genome-wide dataset in the TCGA-based cohorts were divided into 2 groups in accordance with the median prognostic *KIF* genetic values. GSEA outcomes of the TCGA cohort are shown in [Figures 7A--7L](#f7-medscimonit-24-9442){ref-type="fig"}, [8A--8L](#f8-medscimonit-24-9442){ref-type="fig"} and [9A--9F](#f9-medscimonit-24-9442){ref-type="fig"}), which suggested that their elevated expression remained linked with mismatch repair, P53 regulation pathway, and cell cycle progression.

Nomogram analysis
-----------------

The nomogram was driven from rms as well as its supplementary packages on the base of information of patients having BC with comprehensive clinical evidence within TCGA. It showed that, among the 5 *KIF* genes, *KIF4A* had the greatest sum of risk points (ranging between 0 and 100), while the other genes made a considerably lower contribution ([Figure 10A](#f10-medscimonit-24-9442){ref-type="fig"}). By examining the conformity and discrimination using the nomogram model, bootstrap analysis on the bases of 1000 resampling tests had a C-index of 0.76 and 95% CI of 0.70--0.82. The discrimination is suitable. The calibration curve showed that the general point was close to the ideal curve of 45 degrees, indicating good compliance ([Figure 10B, 10C](#f10-medscimonit-24-9442){ref-type="fig"}).

Discussion
==========

Kinesin motor activity is spatially as well as temporally controlled within mitosis to ensure that it occurs precisely with stable inward and outward forces. Nevertheless, over-expression of a few mitotic kinesins might produce further outward forces. This provokes a sequence of undesirable events, such as overshooting before anaphase, sister chromatid segregation before anaphase, increased spindle separation, and ultimately monopolar or bipolar spindle formation \[[@b28-medscimonit-24-9442]. Such things might cause imbalanced distribution of DNA, aneuploidy and a plethora of cancer phenotypes, together with metastatic and invasive behavior. Kinesin function might cause failed cytokinesis, imperfect spindle assembly and mitotic arrest, which stimulates apoptosis and killing of cancer cells \[[@b15-medscimonit-24-9442]\]. Our evaluation of genetic function enrichment suggested that the KIF gene family is involved in biological processes of the cell cycle such as mitotic cytokinesis, mitotic spindle assembly, and positive regulation of cytokinesis. Our analysis established that *KIF15*, *KIF20A*, *KIF23*, *KIF2C* and *KIF4A* were co-expressed at the protein and gene levels.

We found 5 KIF genes of diagnostic and prognostic value. Extensive studies have reported these genes as potential diagnostic markers in multiple cancers. Among the 5 genes, *KIF15* is likewise overexpressed in lung adenocarcinoma and might play a significant role in modifying the cell cycle \[[@b29-medscimonit-24-9442]\]. Likewise, *KIF15* promotes proliferation of pancreatic cancer cells via the MEK/ERK pathway \[[@b30-medscimonit-24-9442]\]. *KIF15* is overexpressed in BC cells and might have potential as a novel therapeutic target and a prognostic factor in endocrine-therapy-resistant BC \[[@b31-medscimonit-24-9442]\]. We found that expression of *KIF15* mRNA was significantly higher in BC than in adjacent tissues, and elevated expression of *KIF15* in patients with BC was associated with poor OS. Our results agreed with previous studies that designated the *KIF15* as an oncogene in BC.

In 2005, a study by Keisuke et al. \[[@b32-medscimonit-24-9442]\] found that *KIF20A* was overexpressed in pancreatic cancer according to cDNA microarray analysis, and down-regulation of *KIF20A* significantly decreased tumor cell proliferation, confirming that *KIF20A* is carcinogenic in pancreatic cancer. Numerous studies have shown that *KIF20A* also has carcinogenic traits in various other cancers, such as nasopharyngeal carcinoma, liver cancer, melanoma, lung adenocarcinoma and glioma \[[@b33-medscimonit-24-9442]\]. It has been suggested that the *KIF20A* gene is a potential diagnostic biomarker. We found that *KIF20A* has differential expression in BC and adjacent tissues, and high expression of *KIF20A* is related to poor OS in patients with BC, so it might also be a prognostic biomarker.

It has been found that *KIF23* is up-regulated in patients with hepatocellular carcinoma, and it may be a marker for OS \[[@b34-medscimonit-24-9442]\]. Zou et al. \[[@b31-medscimonit-24-9442]\] showed that *KIF4A*, *KIF15*, *KIF20A* and *KIF23* expression was significant in proliferating BC cells. They also showed that, among patients treated with tamoxifen, high expression of these 4 genes was highly correlated with poor recurrence-free survival. It has been suggested that over-expression of *KIF23* is a valuable independent prognostic factor in lung tumors, particularly lung adenocarcinoma, and patients with p-stage I tumor stage and high expression of *KIF23* have poorer survival than those with low expression \[[@b35-medscimonit-24-9442]\]. In addition, the multivariate Cox proportional hazards model in our study, which was based on expression of *KIF23*, likewise divided patients in low- and high-expression groups, and patients with high expression had poor OS.

Nowadays, it is certain that *KIF4A* performs a significant role in cancer development and progression. Numerous studies have shown that *KIF4A* is a potential contributor to several malignant tumors, such as lung cancer \[[@b36-medscimonit-24-9442]\], breast cancer \[[@b37-medscimonit-24-9442]\], cervical cancer \[[@b38-medscimonit-24-9442]\], hepatocellular carcinoma \[[@b39-medscimonit-24-9442]\], and oral cancer \[[@b40-medscimonit-24-9442]\]. Our results were consistent with previous studies. We also found that BC patients with high expression of *KIF4A* had poor OS compared with patients with low expression.

Shimo et al. have demonstrated that *KIF2C* is overexpressed in BC cells, and plays a major part in cytokinesis within these cells \[[@b41-medscimonit-24-9442]\]. Additionally, they have discovered that down-regulation of *KIF2C* through treatment with siRNA suppresses development of BC cells \[[@b41-medscimonit-24-9442]\]. We investigated the high expression of *KIF4A*, *KIF15*, *KIF20A*, *KIF23* and *KIF2C* in patients in the TCGA database, which has been linked to poor OS. Our joint genetic analysis suggests that BC patients with high expression of 2--5 of these genes have poorer OS compared with patients with low gene expression. These findings suggest *KIF4A*, *KIF15*, *KIF20A*, *KIF23* and *KIF2C* as potential prognostic biomarkers and therapeutic targets in BC.

GSEA showed that *KIF4A*, *KIF15*, *KIF20A*, *KIF23* and *KIF2C* were significantly associated with the cell cycle, p53 and mismatch repair, that were associated with their biological functioning. It is well known that KIF genes play critical roles in DNA replication and cell cycle progression \[[@b15-medscimonit-24-9442]\]. The results require additional experimental validation.

The present study had a few limitations. First, all the information was obtained from open databases, and the medical parameters were not complete. Therefore, we were not able to perform a far-reaching survival analysis of *KIF* genes, considering each latent prognostic variable of BC in the multivariate Cox proportional hazards regression model. Second, because of the varied origin of BC patients, together with the number of elements affecting BC prognosis, we were not able to construct a comprehensive hazard score model, which depended on the KIF genes articulation level for visualization forecast. Third, with the help of the correlation with the past research work, the constraint of our present investigation suggested that it just researched the relationship existing between the mRNA expression of the KIF genes and BC prognosis. Nonetheless, the connection between KIF protein level and BC requires additional investigation.

In spite of the above limitations, we established and validated the prognostic and diagnostic values of expression of KIF genes in BC patients, and similarly examined the potential mechanism linked with *KIF4A*, *KIF15*, *KIF20A*, *KIF23* and *KIF2C* within BC prognosis by GSEA. When these outcomes are confirmed, the prognostic and diagnostic standards of KIF genetics on the extent of protein, such genes might hold a substantial clinical implication value in diagnosis of BC, as well as targeted therapy. Nevertheless, future verification with a larger study population is required to confirm that the KIF genes could be involved in diagnosis and prognostic monitoring of BC.

Conclusions
===========

We revealed that 13 KIF genes were differentially expressed in BC tumor tissues, and may serve as latent diagnostic biomarkers in patients with BC. *KIF15*, *KIF20A*, *KIF23*, *KIF2C* and *KIF4A* have the potential to serve as prognostic biomarkers in patients with BC. Multivariate survival analysis, nomograms, and joint survival analysis showed high expression of these genes correlated with poor prognosis of BC. GO, KEGG and GSEA suggested that these genes affect the prognosis of BC by influencing the cell cycle. Our results need to be confirmed in further research.
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![GO term and KEGG analysis of all the KIF family genes. GO term enrichments of KIF genes: (**A**) for MF; (**B**) for CC; (**C**) for BP. (**D**) KEGG enrichments of KIF genes. GO -- gene ontology; KEGG -- Kyoto Encyclopedia of Genes and Genomes; KIF -- kinesin; MF -- molecular function; CC -- cellular component; BP -- biological process.](medscimonit-24-9442-g001){#f1-medscimonit-24-9442}

![Protein--protein and gene--gene interaction networks of KIF genes. (**A**) GeneMANIA interaction networks. (**B**) Protein--protein interaction networks; (**C**) BiNGO analysis. KIF -- kinesin; BiNGO -- Biological Networks Gene Ontology tool.](medscimonit-24-9442-g002){#f2-medscimonit-24-9442}

![(**A**) Expression of KIF family genes. (**B**) Gene expression distribution of KIF genes in TCGA. \* *P*\<0.01. KIF -- kinesin; TCGA -- the Cancer Genome Atlas.](medscimonit-24-9442-g003){#f3-medscimonit-24-9442}

![ROC curves (AUC\>0.9) of KIF gens for distinguishing BC tumor tissue and adjacent normal tissues in TCGA. ROC curves of *KIF2C* (**A**), *KIF4A* (**B**), *KIFC1* (**C**), *KIF18B* (**D**), *KIF20A* (**E**), *KIF23* (**F**), *KIF11* (**G**), *KIF14* (**H**), *KIF15* (**I**), *KIF18A* (**J**), and *KIF26B* (**K**). KIF -- kinesin; TCGA -- the Cancer Genome Atlas; BC -- breast cancer; AUC -- area under the curve; ROC -- receiver operating characteristic.](medscimonit-24-9442-g004){#f4-medscimonit-24-9442}

![Kaplan-Meier survival curves for KIF genes in BC of TCGA cohort. OS stratified by *KIF15* (**A**), *KIF20A* (**B**), *KIF23* (**C**), *KIF2C* (**D**), and *KIF4A* (**E**). KIF -- kinesin; TCGA -- the Cancer Genome Atlas; BC -- breast cancer; OS -- overall survival.](medscimonit-24-9442-g005){#f5-medscimonit-24-9442}

![Co-expression heat map of *KIF2C*, *KIF4A*, *KIF23*, *KIF20A* and *KIF15* in TCGA BC patients. KIF -- kinesin; TCGA -- the Cancer Genome Atlas; BC -- breast cancer.](medscimonit-24-9442-g006){#f6-medscimonit-24-9442}

![**A--F** shows GSEA of *KIF2C* in TCGA patients. (**A--D**) GSEA results of c2 reference gene sets for high *KIF2C* expression groups, (**E--F**) GSEA results of c5 reference gene sets for high *KIF2C* expression groups; **G--L** shows GSEA of *KIF4A* in TCGA patients. (**G--J**) GSEA results of c2 reference gene sets for high *KIF4A* expression groups; (**K--L**) GSEA results of c5 reference gene sets for high *KIF4A* expression groups. KIF -- kinesin; GSEA -- gene set enrichment analysis; TCGA -- the Cancer Genome Atlas; BC -- breast cancer.](medscimonit-24-9442-g007){#f7-medscimonit-24-9442}

![**A--F** shows GSEA of *KIF15* in TCGA patients. (**A--D**) GSEA results of c2 reference gene sets for high *KIF15* expression groups. (**E--F**) GSEA results of c5 reference gene sets for high *KIF15* expression groups. **G--L** shows GSEA of *KIF20A* in TCGA patients. (**G--J**) GSEA results of c2 reference gene sets for high *KIF20A* expression groups. (**K--L**) GSEA results of c5 reference gene sets for high *KIF20A* expression groups. KIF -- kinesin; GSEA -- gene set enrichment analysis; TCGA -- the Cancer Genome Atlas; BC -- breast cancer.](medscimonit-24-9442-g008){#f8-medscimonit-24-9442}

![GSEA results of *KIF23* in TCGA BC patients. (**A--D**) GSEA results of c2 reference gene sets for high *KIF23* expression groups. (**E--F**) GSEA results of c5 reference gene sets for high *KIF23* expression groups. KIF -- kinesin; GSEA -- gene set enrichment analysis; TCGA -- the Cancer Genome Atlas; BC -- breast cancer.](medscimonit-24-9442-g009){#f9-medscimonit-24-9442}

![(**A--C**) Relationship between risk score and clinical information. Nomogram for predicting the 1-, 3-, and 5-year event (death) with risk score and clinical information. OS -- overall survival.](medscimonit-24-9442-g010){#f10-medscimonit-24-9442}

###### 

The difference expression between BC patients and normal breast tissues.

  Gene name   log2 fold change   P value   FDR     AUC     95%CI          P value
  ----------- ------------------ --------- ------- ------- -------------- ---------
  KIF4A       3.815              0.000     0.000   0.979   0.969--0.988   0.000
  KIFC1       3.134              0.000     0.000   0.968   0.956--0.980   0.000
  KIF18B      3.545              0.000     0.000   0.967   0.951--0.983   0.000
  KIF2C       3.302              0.000     0.000   0.967   0.954--0.980   0.000
  KIF20A      3.352              0.000     0.000   0.964   0.948--0.980   0.000
  KIF23       2.609              0.000     0.000   0.962   0.949--0.975   0.000
  KIF11       2.488              0.000     0.000   0.961   0.945--0.977   0.000
  KIF14       3.489              0.000     0.000   0.955   0.938--0.973   0.000
  KIF22       1.450              0.000     0.000   0.950   0.936--0.965   0.000
  KIF15       2.519              0.000     0.000   0.943   0.924--0.962   0.000
  KIF18A      2.405              0.000     0.000   0.935   0.917--0.952   0.000
  KIF24       1.563              0.002     0.013   0.929   0.911--0.948   0.000
  KIF26B      2.793              0.000     0.000   0.927   0.909--0.944   0.000
  KIFC2       2.087              0.000     0.000   0.880   0.857--0.904   0.000
  KIF26A      −1.291             0.006     0.027   0.867   0.840--0.895   0.000
  KIF13A      −0.716             0.001     0.006   0.859   0.931--0.887   0.000
  KIF17       −1.062             0.132     0.305   0.829   0.794--0.865   0.000
  KIF25       −1.970             0.018     0.066   0.809   0.771--0.848   0.000
  KIF1B       −0.693             0.002     0.013   0.797   0.763--0.832   0.000
  KIF4B       2.058              0.298     0.532   0.781   0.744--0.818   0.000
  KIF20B      0.825              0.027     0.092   0.765   0.730--0.800   0.000
  KIF19       −0.436             0.534     0.747   0.757   0.724--0.790   0.000
  KIF1C       −0.715             0.000     0.002   0.738   0.691--0.785   0.000
  KIF21A      0.815              0.007     0.032   0.733   0.699--0.767   0.000
  KIFAP3      0.395              0.096     0.242   0.720   0.686--0.754   0.000
  KIF5A       −0.338             0.475     0.702   0.707   0.657--0.757   0.000
  KIFC3       −0.346             0.261     0.486   0.704   0.664--0.743   0.000
  KIF9        0.507              0.367     0.605   0.684   0.645--0.724   0.000
  KIF7        −0.322             0.377     0.616   0.679   0.637--0.721   0.000
  KIF3B       0.352              0.071     0.194   0.665   0.629--0.700   0.000
  KIF13B      −0.027             0.815     0.927   0.626   0.592--0.659   0.000
  KIF3A       0.348              0.343     0.580   0.617   0.569--0.664   0.000
  KIF1BP      0.183              0.414     0.651   0.612   0.568--0.656   0.000
  KIF12       1.161              0.000     0.002   0.605   0.557--0.653   0.000
  KIF1A       4.263              0.000     0.000   0.604   0.565--0.644   0.000
  KIF27       −0.115             0.693     0.857   0.598   0.545--0.652   0.001
  KIF3C       0.444              0.182     0.381   0.568   0.532--0.604   0.018
  KIF5B       −0.040             0.903     0.977   0.553   0.504--0.601   0.065
  KIF16B      0.292              0.219     0.433   0.536   0.498--0.574   0.211
  KIF21B      0.436              0.437     0.671   0.510   0.470--0.550   0.722
  KIF6        0.406              0.772     0.904   0.509   0.471--0.547   0.765
  KIF2A       0.065              0.772     0.904   0.507   0.465--0.549   0.805
  KIF5C       0.742              0.023     0.083   0.506   0.463--0.550   0.826

FDR -- false discovery rate; AUC -- area under the curve; 95%CI -- 95% confidence interval.

###### 

Demographic and clinical data for 1055 BC patients.

  Variables     Patients (n=1055)   No. of events   MST (days)   HR (95% CI)              Log-rank P
  ------------- ------------------- --------------- ------------ ------------------------ ------------
  Race                                                                                    0.534
   White        732                 109             3941         Ref                      
   Others       239                 33              3873         1.132 (0.766--1.671)     
   Missing      84                                                                        
  Gender                                                                                  0.854
   Female       1043                148             3926         Ref                      
   Male         12                  1               NA           0.832 (0.116--5.96)      
  Age (years)                                                                             \<0.001
   ≥65          719                 88              6456         Ref                      
   \<65         322                 61              3418         2.18 (1.567--3.033)      
   Missing      14                                                                        
  Tumor stage                                                                             \<0.001
   I            175                 15              3959         Ref                      
   II           596                 65              4267         1.71 (0.974--2.999)      
   III          241                 43              3461         3.131 (1.738--5.641)     
   IV           20                  15              1034         13.481 (6.572--27.654)   
   Missing      23                                                                        

MST -- median survival time; HR -- hazard ratio; CI -- confidence interval.

###### 

Prognostic survival analysis according to the high or low level of 13 diagnostic KIF genes and OS.

  Gene     Patients (n=1055)   Events   MST (days)   Crude HR (95% CI)      Crude P     Adjusted HR[\*](#tfn3-medscimonit-24-9442){ref-type="table-fn"} (95% CI)[\*](#tfn3-medscimonit-24-9442){ref-type="table-fn"}   Adjusted P[\*](#tfn3-medscimonit-24-9442){ref-type="table-fn"}
  -------- ------------------- -------- ------------ ---------------------- ----------- ------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------
  KIF11                                                                                                                                                                                                                
   High    527                 82       4456         **1**                              **1**                                                                                                                          
   Low     528                 67       3736         1.106 (0.801--1.529)   0.54        1.402 (0.991--1.982)                                                                                                           0.056
  KIF14                                                                                                                                                                                                                
   High    527                 76       7455         **1**                              **1**                                                                                                                          
   Low     528                 73       3736         1.028 (0.745--1.417)   0.869       1.187 (0.848--1.663)                                                                                                           0.318
  KIF15                                                                                                                                                                                                                
   High    527                 80       6593         **1**                              **1**                                                                                                                          
   Low     528                 69       3736         1.068 (0.773--1.476)   0.688       1.422 (1.007--2.008)                                                                                                           **0.045**
  KIF18A                                                                                                                                                                                                               
   High    527                 82       3945         **1**                              **1**                                                                                                                          
   Low     528                 67       3736         1.105 (0.799--1.527)   0.546       1.367 (0.971--1.924)                                                                                                           0.073
  KIF18B                                                                                                                                                                                                               
   High    527                 78       3959         **1**                              **1**                                                                                                                          
   Low     528                 71       3736         1.143 (0.829--1.577)   0.415       1.224 (0.875--1.713)                                                                                                           0.238
  KIF1A                                                                                                                                                                                                                
   High    527                 74       3945         **1**                              **1**                                                                                                                          
   Low     528                 75       3926         1.001 (0.726--1.38)    0.996       1.046 (0.748--1.461)                                                                                                           0.794
  KIF20A                                                                                                                                                                                                               
   High    527                 87       3959         **1**                              **1**                                                                                                                          
   Low     528                 62       3736         1.273 (0.917--1.766)   0.148       1.467 (1.038--2.072)                                                                                                           **0.03**
  KIF23                                                                                                                                                                                                                
   High    527                 83       3959         **1**                              **1**                                                                                                                          
   Low     528                 66       3736         1.23 (0.889--1.701)    0.21        1.54 (1.09--2.175)                                                                                                             **0.014**
  KIF26B                                                                                                                                                                                                               
   High    527                 69       3472         **1**                              **1**                                                                                                                          
   Low     528                 80       3959         1.067 (0.771--1.475)   0.696       1.194 (0.848--1.682)                                                                                                           0.309
  KIF2C                                                                                                                                                                                                                
   High    527                 84       3959         **1**                              **1**                                                                                                                          
   Low     528                 65       3926         1.341 (0.97--1.855)    0.075       1.805 (1.276--2.553)                                                                                                           **0.001**
  KIF4A                                                                                                                                                                                                                
   High    527                 90       3941         **1**                              **1**                                                                                                                          
   Low     528                 59       3926         1.557 (1.121--2.162)   **0.008**   1.805 (1.276--2.553)                                                                                                           **0.001**
  KIFC1                                                                                                                                                                                                                
   High    527                 82       4456         **1**                              **1**                                                                                                                          
   Low     528                 67       3492         1.106 (0.798--1.534)   0.545       1.273 (0.902--1.796)                                                                                                           0.17
  KIFC2                                                                                                                                                                                                                
   High    527                 71       4456         **1**                              **1**                                                                                                                          
   Low     528                 78       3669         0.983 (0.712--1.358)   0.919       0.915 (0.653--1.281)                                                                                                           0.603

Adjusted for age (stratified by 65 years) and tumor stage. KIF -- kinesin; OS -- overall survival; MST -- median survival time; HR -- hazard ratio; CI -- confidence interval.

###### 

Grouping according to 2 selected genes.

  Group                     Combination                Group   Combination
  ------------------------- -------------------------- ------- --------------------------
  1                         Low KIF15 + low KIF20A     16      Low KIF20A + low KIF2C
  2                         Low KIF15 + high KIF20A    17      Low KIF20A + high KIF2C
  High KIF15 + low KIF20A   High KIF20A + low KIF2C            
  3                         High KIF15 + high KIF20A   18      High KIF20A + high KIF2C
  4                         Low KIF15 + low KIF23      19      Low KIF20A + low KIF4A
  5                         Low KIF15 + high KIF23     20      Low KIF20A + high KIF4A
  High KIF15 + low KIF23    High KIF20A + low KIF4A            
  6                         High KIF15 + high KIF23    21      High KIF20A + high KIF4A
  7                         Low KIF15 + low KIF2C      22      Low KIF23 + low KIF2C
  8                         Low KIF15 + high KIF2C     23      Low KIF23 + high KIF2C
  High KIF15 + low KIF2C    High KIF23 + low KIF2C             
  9                         High KIF15 + high KIF2C    24      High KIF23 + high KIF2C
  10                        Low KIF15 + low KIF4A      25      Low KIF23 + low KIF4A
  11                        Low KIF15 + high KIF4A     26      Low KIF23 + high KIF4A
  High KIF15 + low KIF4A    High KIF23 + low KIF4A             
  12                        High KIF15 + high KIF4A    27      High KIF23 + high KIF4A
  13                        Low KIF20A + low KIF23     28      Low KIF2C + low KIF4A
  14                        Low KIF20A + high KIF23    29      Low KIF2C + high KIF4A
  High KIF20A + low KIF23   High KIF2C + low KIF4A             
  15                        High KIF20A + high KIF23   30      High KIF2C + high KIF4A

KIF -- kinesin.

###### 

Grouping according to 3 selected genes.

  Group                                  Combination                             Group   Combination
  -------------------------------------- --------------------------------------- ------- ---------------------------------------
  a                                      Low KIF15 + low KIF20A + low KIF23      A       Low KIF15 + low KIF2C + low KIF4A
  b                                      Low KIF15 + high KIF20A + low KIF23     B       High KIF15 + low KIF2C + low KIF4A
  High KIF15 + low KIF20A + low KIF23    Low KIF15 + high KIF2C + low KIF4A              
  Low KIF15 + low KIF20A + high KIF23    Low KIF15 + low KIF2C + high KIF4A              
  High KIF15 + high KIF20A + low KIF23   High KIF15 + high KIF2C + low KIF4A             
  Low KIF15 + high KIF20A + high KIF23   High KIF15 + low KIF2C + high KIF4A             
  High KIF15 + low KIF20A + high KIF23   Low KIF15 + high KIF2C + high KIF4A             
  c                                      High KIF15 + high KIF20A + high KIF23   C       High KIF15 + high KIF2C + high KIF4A
  d                                      Low KIF15 + low KIF20A + low KIF2C      D       Low KIF20A + low KIF23 + low KIF2C
  e                                      High KIF15 + high KIF20A + low KIF2C    E       High KIF20A + low KIF23 + low KIF2C
  Low KIF15 + high KIF20A + low KIF2C    Low KIF20A + high KIF23 + low KIF2C             
  High KIF15 + low KIF20A + low KIF2C    Low KIF20A + low KIF23 + high KIF2C             
  Low KIF15 + high KIF20A + high KIF2C   High KIF20A + high KIF23 + low KIF2C            
  High KIF15 + low KIF20A + high KIF2C   High KIF20A + low KIF23 + high KIF2C            
  Low KIF15 + low KIF20A + high KIF2C    Low KIF20A + high KIF23 + high KIF2C            
  f                                      High KIF15 + high KIF20A + high KIF2C   F       High KIF20A + high KIF23 + high KIF2C
  g                                      Low KIF15 + low KIF20A + low KIF4A      G       Low KIF20A + low KIF23 + low KIF4A
  h                                      Low KIF15 + high KIF20A + low KIF4A     H       High KIF20A + low KIF23 + low KIF4A
  High KIF15 + low KIF20A + low KIF4A    Low KIF20A + high KIF23 + low KIF4A             
  Low KIF15 + high KIF20A + high KIF4A   Low KIF20A + low KIF23 + high KIF4A             
  High KIF15 + low KIF20A + high KIF4A   High KIF20A + high KIF23 + low KIF4A            
  High KIF15 + high KIF20A + low KIF4A   High KIF20A + low KIF23 + high KIF4A            
  Low KIF15 + low KIF20A + high KIF4A    Low KIF20A + high KIF23 + high KIF4A            
  i                                      High KIF15 + high KIF20A + high KIF4A   I       High KIF20A + high KIF23 + high KIF4A
  j                                      Low KIF15 + low KIF23 + low KIF2C       J       Low KIF20A + low KIF2C + low KIF4A
  k                                      High KIF15 + low KIF23 + low KIF2C      K       High KIF20A + low KIF2C + low KIF4A
  Low KIF15 + high KIF23 + low KIF2C     Low KIF20A + high KIF2C + low KIF4A             
  Low KIF15 + low KIF23 + high KIF2C     Low KIF20A + low KIF2C + high KIF4A             
  High KIF15 + high KIF23 + low KIF2C    High KIF20A + high KIF2C + low KIF4A            
  High KIF15 + low KIF23 + high KIF2C    High KIF20A + low KIF2C + high KIF4A            
  Low KIF15 + high KIF23 + high KIF2C    Low KIF20A + high KIF2C + high KIF4A            
  l                                      High KIF15 + high KIF23 + high KIF2C    L       High KIF20A + high KIF2C + high KIF4A
  m                                      Low KIF15 + low KIF23 + low KIF4A       M       Low KIF23 + low KIF2C + low KIF4A
  n                                      High KIF15 + low KIF23 + low KIF4A      N       Low KIF23 + low KIF2C + high KIF4A
  Low KIF15 + high KIF23 + low KIF4A     High KIF23 + low KIF2C + low KIF4A              
  Low KIF15 + low KIF23 + high KIF4A     Low KIF23 + high KIF2C + low KIF4A              
  High KIF15 + high KIF23 + low KIF4A    High KIF23 + high KIF2C + low KIF4A             
  High KIF15 + high KIF23 + high KIF4A   High KIF23 + low KIF2C + high KIF4A             
  Low KIF15 + high KIF23 + high KIF4A    Low KIF23 + high KIF2C + high KIF4A             
  o                                      High KIF15 + low KIF23 + high KIF4A     O       High KIF23 + high KIF2C + high KIF4A

KIF -- kinesin.

###### 

Grouping according to 4 selected genes.

  Group                                               Combination                                          Group   Combination
  --------------------------------------------------- ---------------------------------------------------- ------- ----------------------------------------------------
  I                                                   Low KIF15 + low KIF20A + low KIF23 + low KIF2C       X       Low KIF15 + low KIF23 + low KIF2C + low KIF4A
  II                                                  High KIF15 + high KIF20A + low KIF23 + low KIF2C     XI      High KIF15 + low KIF23 + low KIF2C + low KIF4A
  Low KIF15 + high KIF20A + high KIF23 + high KIF2C   High KIF15 + low KIF23 + high KIF2C + high KIF4A             
  High KIF15 + low KIF20A + high KIF23 + high KIF2C   High KIF15 + high KIF23 + low KIF2C + high KIF4A             
  High KIF15 + high KIF20A + low KIF23 + high KIF2C   High KIF15 + high KIF23 + high KIF2C + low KIF4A             
  High KIF15 + high KIF20A + high KIF23 + low KIF2C   Low KIF15 + high KIF23 + low KIF2C + high KIF4A              
  Low KIF15 + high KIF20A + low KIF23 + high KIF2C    Low KIF15 + high KIF23 + high KIF2C + low KIF4A              
  Low KIF15 + high KIF20A + high KIF23 + low KIF2C    High KIF15 + low KIF23 + high KIF2C + low KIF4A              
  High KIF15 + low KIF20A + high KIF23 + low KIF2C    High KIF15 + low KIF23 + low KIF2C + high KIF4A              
  High KIF15 + low KIF20A + low KIF23 + high KIF2C    High KIF15 + high KIF23 + low KIF2C + low KIF4A              
  High KIF15 + low KIF20A + low KIF23 + low KIF2C     Low KIF15 + high KIF23 + low KIF2C + low KIF4A               
  Low KIF15 + high KIF20A + low KIF23 + low KIF2C     Low KIF15 + low KIF23 + high KIF2C + low KIF4A               
  Low KIF15 + low KIF20A + high KIF23 + low KIF2C     Low KIF15 + low KIF23 + low KIF2C + high KIF4A               
  Low KIF15 + low KIF20A + low KIF23 + high KIF2C     Low KIF15 + low KIF23 + high KIF2C + high KIF4A              
  Low KIF15 + low KIF20A + high KIF23 + high KIF2C    Low KIF15 + high KIF23 + high KIF2C + high KIF4A             
  III                                                 High KIF15 + high KIF20A + high KIF23 + high KIF2C   XII     High KIF15 + high KIF23 + high KIF2C + high KIF4A
  IV                                                  Low KIF15 + low KIF20A + low KIF23 + low KIF4A       XIII    Low KIF20A + low KIF23 + low KIF2C + low KIF4A
  V                                                   High KIF15 + high KIF20A + low KIF23 + low KIF4A     XIV     High KIF20A + low KIF23 + low KIF2C + low KIF4A
  Low KIF15 + high KIF20A + high KIF23 + high KIF4A   High KIF20A + low KIF23 + high KIF2C + high KIF4A            
  High KIF15 + low KIF20A + high KIF23 + high KIF4A   High KIF20A + high KIF23 + low KIF2C + high KIF4A            
  High KIF15 + high KIF20A + low KIF23 + high KIF4A   High KIF20A + high KIF23 + high KIF2C + low KIF4A            
  High KIF15 + high KIF20A + high KIF23 + low KIF4A   Low KIF20A + high KIF23 + low KIF2C + high KIF4A             
  Low KIF15 + high KIF20A + low KIF23 + high KIF4A    Low KIF20A + high KIF23 + high KIF2C + low KIF4A             
  Low KIF15 + high KIF20A + high KIF23 + low KIF4A    High KIF20A + low KIF23 + high KIF2C + low KIF4A             
  High KIF15 + low KIF20A + high KIF23 + low KIF4A    High KIF20A + low KIF23 + low KIF2C + high KIF4A             
  High KIF15 + low KIF20A + low KIF23 + high KIF4A    High KIF20A + high KIF23 + low KIF2C + low KIF4A             
  High KIF15 + low KIF20A + low KIF23 + low KIF4A     Low KIF20A + high KIF23 + low KIF2C + low KIF4A              
  Low KIF15 + high KIF20A + low KIF23 + low KIF4A     Low KIF20A + low KIF23 + high KIF2C + low KIF4A              
  Low KIF15 + low KIF20A + high KIF23 + low KIF4A     Low KIF20A + low KIF23 + low KIF2C + high KIF4A              
  Low KIF15 + low KIF20A + low KIF23 + high KIF4A     Low KIF20A + low KIF23 + high KIF2C + high KIF4A             
  Low KIF15 + low KIF20A + high KIF23 + high KIF4A    Low KIF20A + high KIF23 + high KIF2C + high KIF4A            
  VI                                                  High KIF15 + high KIF20A + high KIF23 + high KIF4A   XV      High KIF20A + high KIF23 + high KIF2C + high KIF4A
  VII                                                 Low KIF15 + low KIF20A + low KIF2C + low KIF4A               
  VIII                                                High KIF15 + high KIF20A + low KIF2C + low KIF4A             
  Low KIF15 + high KIF20A + high KIF2C + high KIF4A                                                                
  High KIF15 + low KIF20A + high KIF2C + high KIF4A                                                                
  High KIF15 + high KIF20A + low KIF2C + high KIF4A                                                                
  High KIF15 + high KIF20A + high KIF2C + low KIF4A                                                                
  Low KIF15 + high KIF20A + low KIF2C + high KIF4A                                                                 
  Low KIF15 + high KIF20A + high KIF2C + low KIF4A                                                                 
  High KIF15 + low KIF20A + high KIF2C + low KIF4A                                                                 
  High KIF15 + low KIF20A + low KIF2C + high KIF4A                                                                 
  High KIF15 + low KIF20A + low KIF2C + low KIF4A                                                                  
  Low KIF15 + high KIF20A + low KIF2C + low KIF4A                                                                  
  Low KIF15 + low KIF20A + high KIF2C + low KIF4A                                                                  
  Low KIF15 + low KIF20A + low KIF2C + high KIF4A                                                                  
  Low KIF15 + low KIF20A + high KIF2C + high KIF4A                                                                 
  IX                                                  High KIF15 + high KIF20A + high KIF2C + high KIF4A           

KIF -- kinesin.

###### 

Grouping according to 5 selected genes.

  Group                                                            Combination
  ---------------------------------------------------------------- -----------------------------------------------------------------
  ➀                                                                Low KIF15 + low KIF20A + low KIF23 + low KIF2C + low KIF4A
  ➁                                                                High KIF15 + high KIF20A + low KIF23 + low KIF2C + low KIF4A
  High KIF15 + low KIF20A + low KIF23 + low KIF2C + low KIF4A      
  Low KIF15 + high KIF20A + low KIF23 + low KIF2C + low KIF4A      
  Low KIF15 + low KIF20A + high KIF23 + low KIF2C + low KIF4A      
  Low KIF15 + low KIF20A + low KIF23 + high KIF2C + low KIF4A      
  Low KIF15 + low KIF20A + low KIF23 + low KIF2C + high KIF4A      
  High KIF15 + low KIF20A + high KIF23 + low KIF2C + low KIF4A     
  High KIF15 + low KIF20A + low KIF23 + high KIF2C + low KIF4A     
  High KIF15 + low KIF20A + low KIF23 + low KIF2C + high KIF4A     
  Low KIF15 + high KIF20A + high KIF23 + low KIF2C + low KIF4A     
  Low KIF15 + high KIF20A + low KIF23 + high KIF2C + low KIF4A     
  Low KIF15 + high KIF20A + low KIF23 + low KIF2C + high KIF4A     
  Low KIF15 + low KIF20A + high KIF23 + high KIF2C + low KIF4A     
  Low KIF15 + low KIF20A + high KIF23 + low KIF2C + high KIF4A     
  Low KIF15 + low KIF20A + low KIF23 + high KIF2C + high KIF4A     
  Low KIF15 + high KIF20A + low KIF23 + high KIF2C + high KIF4A    
  Low KIF15 + high KIF20A + high KIF23 + low KIF2C + high KIF4A    
  Low KIF15 + high KIF20A + high KIF23 + high KIF2C + low KIF4A    
  High KIF15 + low KIF20A + low KIF23 + high KIF2C + high KIF4A    
  High KIF15 + low KIF20A + high KIF23 + low KIF2C + high KIF4A    
  High KIF15 + low KIF20A + high KIF23 + high KIF2C + low KIF4A    
  High KIF15 + high KIF20A + low KIF23 + low KIF2C + high KIF4A    
  High KIF15 + high KIF20A + low KIF23 + high KIF2C + low KIF4A    
  High KIF15 + high KIF20A + high KIF23 + low KIF2C + low KIF4A    
  Low KIF15 + high KIF20A + high KIF23 + high KIF2C + high KIF4A   
  High KIF15 + low KIF20A + high KIF23 + high KIF2C + high KIF4A   
  High KIF15 + high KIF20A + low KIF23 + high KIF2C + high KIF4A   
  High KIF15 + high KIF20A + high KIF23 + low KIF2C + high KIF4A   
  High KIF15 + high KIF20A + high KIF23 + high KIF2C + low KIF4A   
  Low KIF15 + low KIF20A + high KIF23 + high KIF2C + high KIF4A    
  ➂                                                                High KIF15 + high KIF20A + high KIF23 + high KIF2C + high KIF4A

KIF -- kinesin.

###### 

Joint analysis of the prognostic value of combination of KIF15, KIF20A, KIF23, KIF2C, and KIF4A expression of BC.

  Group   Patients   MST (days)   Crude p     Crude HR               Adjusted p   Adjusted HR(95% CI) [\*](#tfn8-medscimonit-24-9442){ref-type="table-fn"}
  ------- ---------- ------------ ----------- ---------------------- ------------ --------------------------------------------------------------------------
  1       432        3736         0.367       1                      0.065        1
  2       192        3941         0.185       1.354 (0.865--2.121)   0.16         1.419 (0.87--2.313)
  3       431        6593         0.291       1.219 (0.844--1.759)   **0.021**    1.578 (1.073--2.322)
  4       444        3669         0.439       1                      **0.049**    1
  5       168        4456         0.229       1.328 (0.836--2.11)    0.223        1.363 (0.828--2.245)
  6       443        3959         0.356       1.184 (0.827--1.695)   **0.014**    1.615 (1.1--2.372)
  7       428        3736         0.398       1                      **0.008**    1
  8       200        6456         0.279       1.296 (0.811--2.071)   **0.021**    1.825 (1.097--3.037)
  9       427        3959         0.23        1.244 (0.871--1.778)   **0.003**    1.776 (1.211--2.604)
  10      436        3669         0.237       1                      **0.013**    1
  11      184        6456         0.396       1.223 (0.768--1.946)   0.196        1.39 (0.843--2.29)
  12      435        3873         0.09        1.369 (0.952--1.967)   **0.003**    1.787 (1.215--2.63)
  13      450        3736         0.292       1                      **0.038**    1
  14      156        3461         0.265       1.317 (0.812--2.137)   0.116        1.508 (0.904--2.517)
  15      449        3959         0.14        1.308 (0.916--1.87)    **0.012**    1.625 (1.112--2.374)
  16      441        3736         0.221       1                      **0.008**    1
  17      174        4456         0.546       1.169 (0.704--1.94)    0.652        1.133 (0.659--1.949)
  18      440        3959         0.083       1.366 (0.96--1.944)    **0.003**    1.76 (1.21--2.56)
  19      454        3736         0.051       1                      **0.011**    1
  20      148        6593         0.772       0.919 (0.518--1.631)   0.735        1.114 (0.598--2.074)
  21      453        3941         **0.032**   1.463 (1.034--2.07)    **0.004**    1.715 (1.188--2.475)
  22      445        3736         0.207       1                      **0.006**    1
  23      166        3941         0.197       1.379 (0.846--2.249)   0.394        1.258 (0.742--2.131)
  24      444        3959         0.101       1.344 (0.944--1.914)   **0.002**    1.844 (1.262--2.696)
  25      453        3736         0.070       1                      **0.004**    1
  26      150        NUM          0.805       0.93 (0.525--1.648)    0.932        1.026 (0.573--1.837)
  27      452        3941         **0.040**   1.436 (1.017--2.027)   **0.002**    1.787 (1.236--2.585)
  28      457        3736         **0.033**   1                      **0.001**    1
  29      142        4456         0.751       0.909 (0.505--1.636)   0.457        0.785 (0.414--1.486)
  30      456        3873         **0.020**   1.503 (1.066--2.12)    **0.001**    1.93 (1.34--2.78)
  a       402        3736         0.343       1                      **0.042**    1
  b       258        3941         0.157       1.354 (0.89--2.059)    0.097        1.466 (0.933--2.302)
  c       395        3959         0.298       1.225 (0.836--1.794)   **0.013**    1.674 (1.113--2.516)
  d       390        3736         0.37        1                      **0.04**     1
  e       283        3941         0.232       1.296 (0.847--1.983)   0.129        1.426 (0.902--2.254)
  f       382        3959         0.211       1.274 (0.872--1.861)   **0.011**    1.675 (1.123--2.497)
  g       399        3736         0.335       1                      **0.028**    1
  h       262        4456         0.45        1.181 (0.767--1.818)   0.225        1.335 (0.837--2.131)
  i       394        3959         0.139       1.328 (0.912--1.934)   **0.008**    1.713 (1.152--2.548)
  j       399        3669         0.34        1                      **0.018**    1
  k       267        4456         0.168       1.348 (0.882--2.06)    0.088        1.487 (0.942--2.346)
  l       389        3959         0.262       1.24 (0.851--1.805)    **0.005**    1.787 (1.193--2.675)
  m       403        3669         0.44        1                      **0.019**    1
  n       251        6456         0.519       1.154 (0.747--1.782)   0.316        1.267 (0.798--2.011)
  o       401        3873         0.2         1.275 (0.879--1.849)   **0.006**    1.763 (1.181--2.631)
  A       398        3669         0.334       1                      **0.018**    1
  B       263        6456         0.558       1.14 (0.735--1.767)    0.315        1.273 (0.795--2.04)
  C       394        3959         0.141       1.321 (0.912--1.913)   **0.005**    1.749 (1.18--2.593)
  D       411        3736         0.424       1                      **0.026**    1
  E       248        3941         0.312       1.252 (0.809--1.937)   0.316        1.269 (0.797--2.023)
  F       396        6456         0.225       1.258 (0.869--1.821)   **0.007**    1.721 (1.158--2.559)
  G       419        3736         0.2         1                      **0.023**    1
  H       227        6593         0.885       1.035 (0.649--1.651)   0.46         1.204 (0.735--1.973)
  I       409        3941         0.096       1.358 (0.947--1.949)   **0.007**    1.691 (1.151--2.484)
  J       414        3736         0.081       1                      **0.002**    1
  K       232        4456         0.964       0.989 (0.613--1.597)   0.97         0.99 (0.591--1.658)
  L       409        3873         **0.046**   1.44 (1.006--2.061)    **0.002**    1.823 (1.248--2.664)
  M       419        3736         0.218       1                      **0.002**    1
  N       229        4456         0.891       1.033 (0.646--1.653)   0.965        0.989 (0.6--1.629)
  O       407        3959         0.103       1.346 (0.942--1.925)   **0.002**    1.865 (1.268--2.742)
  I       375        3736         0.391       1                      **0.044**    1
  II      324        3941         0.179       1.324 (0.879--1.995)   0.103        1.44 (0.929--2.231)
  III     356        3959         0.353       1.203 (0.815--1.777)   **0.013**    1.693 (1.115--2.569)
  IV      381        3736         0.477       1                      **0.038**    1
  V       304        4456         0.338       1.224 (0.81--1.852)    0.189        1.347 (0.864--2.099)
  VI      370        3959         0.254       1.252 (0.851--1.843)   **0.01**     1.715 (1.135--2.593)
  VII     375        3736         0.381       1                      **0.037**    1
  VIII    315        4456         0.376       1.208 (0.795--1.837)   0.186        1.355 (0.864--2.124)
  IX      365        3959         0.169       1.309 (0.892--1.921)   **0.01**     1.701 (1.135--2.55)
  X       381        3669         0.544       1                      **0.026**    1
  XI      306        4456         0.441       1.178 (0.776--1.789)   0.257        1.294 (0.829--2.02)
  XII     368        3959         0.285       1.231 (0.841--1.801)   **0.007**    1.752 (1.163--2.638)
  XIII    394        3736         0.41        1                      **0.015**    1
  XIV     287        3941         0.553       1.138 (0.742--1.745)   0.479        1.179 (0.747--1.859)
  XV      374        3959         0.182       1.29 (0.887--1.876)    **0.006**    1.768 (1.182--2.645)
  ➀       364        3736         0.455       1                      **0.045**    1
  ➁       348        3941         0.24        1.275 (0.85--1.912)    0.128        1.4 (0.908--2.158)
  ➂       343        3959         0.316       1.224 (0.824--1.816)   **0.013**    1.708 (1.119--2.606)

Adjusted for age (stratified by 65 years) and tumor stage. KIF -- kinesin; OS -- overall survival; MST -- median survival time; HR -- hazard ratio; CI: confidence interval.
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